<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529395</url>
  </required_header>
  <id_info>
    <org_study_id>GHR 1017</org_study_id>
    <secondary_id>IDRCB 2019-A01978-49</secondary_id>
    <nct_id>NCT04529395</nct_id>
  </id_info>
  <brief_title>Impact of Aromatherapy on the Delirium of Patients in Intensive Care Unit</brief_title>
  <acronym>AROMADELI</acronym>
  <official_title>Impact of Aromatherapy on the Delirium of Patients in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier de la Region de Mulhouse et Sud Alsace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this monocenter randomized controlled trial is to assess the&#xD;
      efficacy of aromatherapy to prevent delirium in patients hospitalized in an intensive care&#xD;
      unit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives:&#xD;
&#xD;
        1. To assess the efficacy of aromatherapy on :&#xD;
&#xD;
             -  the level of consciousness,&#xD;
&#xD;
             -  pain,&#xD;
&#xD;
             -  the duration of mechanical ventilation,&#xD;
&#xD;
             -  the occurence of an accidental extubation,&#xD;
&#xD;
             -  the length of stay in the intensive care unit,&#xD;
&#xD;
             -  the cumulative duration of delirium episodes,&#xD;
&#xD;
             -  the time until first episode of delirium,&#xD;
&#xD;
             -  the use of neuroleptics.&#xD;
&#xD;
        2. To determine the factors influencing the efficacy of aromatherapy.&#xD;
&#xD;
        3. To assess the safety of aromatherapy.&#xD;
&#xD;
      Conduct of research:&#xD;
&#xD;
      After inclusion, patients will be randomized between the aromatherapy and control groups.&#xD;
      Treatment will be started on the same day as randomization.&#xD;
&#xD;
      Aromatherapy treatment will consist of a dermal application on the feet of a mixture of&#xD;
      essential oils.&#xD;
&#xD;
      Control treatment will consist of a dermal application on the feet of apricot vegetable oil.&#xD;
&#xD;
      The mixture of essential oils (aromatherapy group) or vegetable oil (control group) will be&#xD;
      applied to the arch of the foot by massage, every eight hours, at a rate of six drops per&#xD;
      application (3 drops per foot).&#xD;
&#xD;
      Treatment will continue until the patient is discharged from the intensive care unit or no&#xD;
      later than 15 days after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of delirium</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
    <description>The occurrence of delirium will be defined by the presence of at least one episode during the patient's stay in the intensive care unit, diagnosed using the CAM-ICU scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on the Richmond Agitation-Sedation Scale</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Behavior-Pain Scale</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation between admission and first extubation</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of at least one accidental extubation during the stay</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of delirium episodes</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until first episode of delirium</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of neuroleptic treatment</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a local allergic reaction</measure>
    <time_frame>Up to 15 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Intensive Care Unit Delirium</condition>
  <arm_group>
    <arm_group_label>Aromatherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blending of essential oils</intervention_name>
    <description>The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).</description>
    <arm_group_label>Aromatherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apricot vegetable oil</intervention_name>
    <description>The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Patient hospitalized in an intensive care unit for an expected duration of at least 24&#xD;
             hours&#xD;
&#xD;
          -  Patient requiring mechanical ventilation with initial therapeutic sedation adapted&#xD;
             secondarily for comfort sedation, defined by a RASS score target between -2 and 0&#xD;
&#xD;
          -  Patient affiliated to/beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to essential and/or vegetable oils&#xD;
&#xD;
          -  Palliative sedation&#xD;
&#xD;
          -  Foot skin injury contraindicating the application of an oil&#xD;
&#xD;
          -  Moribund patient or expected death&#xD;
&#xD;
          -  History of dementia&#xD;
&#xD;
          -  Participation to a RIPH-1 study&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient under legal protection&#xD;
&#xD;
          -  Patient deprived of liberty by judicial or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaldoun Kuteifan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHRMSA hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Diesel</last_name>
    <phone>+33 3 89 64 84 28</phone>
    <email>marie.diesel@ghrmsa.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier de Mulhouse et de la Région Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khaldoun Kuteifan, MD</last_name>
      <email>KUTEIFANK@ghrmsa.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Delirium</keyword>
  <keyword>Aromatherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

